Luminescence imaging technology developer Lightpoint Medical has signed a collaboration agreement with radiopharmaceutical developer Telix Pharmaceuticals.
Under the agreement, the two firms will seek to integrate Lightpoint's Sensei gamma probe with Telix's investigational SPECT imaging agent TLX599-CDx for intraoperative prostate cancer detection. The companies have the intention of regulatory approval and marketing of a combined product, Lightpoint said.
Sensei is a small surgical gamma probe for robot-assisted cancer surgery. It has been approved for marketing in the U.S., the European Union, the U.K, and Australia, according to Lightpoint.
